This story originally appeared on Zacks
Avid Bioservices (CDMO) closed at $20.24 in the latest trading session, marking a -0.3% move from the prior day. This change lagged the S&P 500’s 2.24% gain on the day. Elsewhere, the Dow gained 2.51%, while the tech-heavy Nasdaq lost 0.17%.
Heading into today, shares of the contract manufacturer had gained 22.07% over the past month, outpacing the Medical sector’s loss of 1% and the S&P 500’s loss of 2.58% in that time.
Wall Street will be looking for positivity from Avid Bioservices as it approaches its next earnings report date. The company is expected to report EPS of $0.05, up 400% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $28 million, up 28.38% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.28 per share and revenue of $117.1 million, which would represent changes of +366.67% and +22.15%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Avid Bioservices. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company’s business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Avid Bioservices is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Avid Bioservices is currently trading at a Forward P/E ratio of 72.5. This valuation marks a premium compared to its industry’s average Forward P/E of 16.51.
The Medical – Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 150, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Avid Bioservices, Inc. (CDMO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research